Literature DB >> 17521906

Chemotherapy in metastatic colorectal cancer.

Claire Kelly1, Jim Cassidy.   

Abstract

This article aims to provide the reader with a broad overview of the current chemotherapeutic options available for the treatment of patients with metastatic colorectal cancer. The review includes discussion of both well established and experimental therapies.

Entities:  

Mesh：

Year:  2007        PMID： 17521906     DOI： 10.1016/j.suronc.2007.04.006

Source DB:  PubMed          Journal:  Surg Oncol        ISSN： 0960-7404            Impact factor:   3.279


  17 in total

Review 1.  Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

Authors:  Britta Kleist; Micaela Poetsch
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.

Authors:  Stefan Madajewicz; David M Waterhouse; Paul S Ritch; M Qaseem Khan; Donald J Higby; Cynthia G Leichman; Sandeep K Malik; Patricia Hentschel; John F Gill; Luping Zhao; Steven J Nicol
Journal:  Invest New Drugs       Date:  2010-12-01       Impact factor: 3.850

Review 3.  Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Authors:  Qi-Bin Song; Qi Wang; Wei-Guo Hu
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers.

Authors:  Jin C Kim; Han C Lee; Dong H Cho; Eun Y Choi; Yoon K Cho; Ye J Ha; Pyong W Choi; Seon A Roh; Seon Y Kim; Yong S Kim
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-18       Impact factor: 4.553

5.  Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis.

Authors:  Linlin Zhang; Li Ma; Qinghua Zhou
Journal:  Int J Colorectal Dis       Date:  2011-04-20       Impact factor: 2.571

6.  The outcome of liver resection and lymphadenectomy for hilar lymph node involvement in colorectal cancer liver metastases.

Authors:  Wei Liu; Xiao-Luan Yan; Kun Wang; Quan Bao; Yi Sun; Bao-Cai Xing
Journal:  Int J Colorectal Dis       Date:  2014-04-18       Impact factor: 2.571

7.  Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis.

Authors:  K A Paschos; N Bird
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

8.  Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.

Authors:  Jin C Kim; Dae D Kim; Yoo M Lee; Tae W Kim; Dong H Cho; Moon B Kim; Seong G Ro; Seon Y Kim; Yong S Kim; Jung S Lee
Journal:  Int J Colorectal Dis       Date:  2008-10-01       Impact factor: 2.571

9.  Functional blocking of specific integrins inhibit colonic cancer migration.

Authors:  John H Robertson; Shi Yu Yang; Marc C Winslet; Alexander M Seifalian
Journal:  Clin Exp Metastasis       Date:  2009-06-26       Impact factor: 5.150

Review 10.  Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.

Authors:  Stuart M Robinson; Colin H Wilson; Alastair D Burt; Derek M Manas; Steven A White
Journal:  Ann Surg Oncol       Date:  2012-07-06       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.